Developer docs
API playgroundTry for free, no card

Search company profiles

MicroPort CRM

Full company profile

uuid00052nh

Namestring
MicroPort CRM
Legal namestring
MicroPort Scientific Corporation
Company typeenum
Private
Founded yearint
2017
Descriptiontext

MicroPort CRM develops, manufactures, and markets a portfolio of implantable cardiac devices for the management of cardiac rhythm disorders and heart failure. The company is headquartered in Clamart, near Paris, France, and operates as the Cardiac Rhythm Management-focused subsidiary of MicroPort Scientific Corporation, a publicly listed Chinese medical device conglomerate. Its product range spans cardiac pacemakers, implantable cardiac defibrillators (including the recently launched ULYS ICD), cardiac resynchronization therapy (CRT) systems for heart failure, and ECG diagnostic solutions, all positioned under a "connectivity-focused" brand thesis. The ULYS ICD and INVICTA defibrillation leads were introduced in Japan in October 2023 following clinical trials that reported a 100% implantation success rate and a 97.4% complication-free rate.

Short descriptiontext

MicroPort CRM is a Clamart, France-based subsidiary of MicroPort Scientific Corporation that develops, manufactures, and markets implantable pacemakers, defibrillators, cardiac resynchronization systems, and ECG diagnostic solutions for hospitals and cardiac centers managing rhythm disorders and heart failure globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
5,001–10,000
akta.pro rankint
HeadquartersClamart, France
HQ citystring
Clamart
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cardiac rhythm management, implantable cardiac devices, cardiac pacemakers, implantable defibrillators, cardiac resynchronization therapy
Industry1 code
1Cardiac Rhythm Management (Pacemakers, ICDs, CRT)
CodeHLAHAFACPrimaryYes
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Cardiac Rhythm Management Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Implantable Cardiac Devices
TypeHardware Sales
Description

Sale of implantable cardiac rhythm management devices including pacemakers, defibrillators, and cardiac resynchronization systems. Revenue is generated through product sales to hospitals and healthcare facilities globally.

microport.com
2ECG Diagnostic Solutions
TypeHardware Sales
Description

Sale of ECG diagnostic equipment and solutions for cardiac rhythm monitoring and diagnosis

microport.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1CardioFlow MedTech
Description

Cardiac rhythm management product brand mentioned on the MicroPort website linking to en.cardioflowmedtech.com

microport.com
Core offering1 text field

MicroPort CRM develops, manufactures, and markets implantable cardiac devices for the management of cardiac rhythm disorders and heart failure. Its portfolio includes cardiac pacemakers, implantable cardiac defibrillators (including the ULYS ICD), defibrillation leads (INVICTA), cardiac resynchronization therapy (CRT) systems, and ECG diagnostic solutions, sold globally to hospitals and cardiac care centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 100% implantation success rate for ULYS ICD in Japan clinical trials
+1 more record
Product overview1 text field

MicroPort® CRM is a pioneering Cardiac Rhythm Management (CRM) company headquartered in Clamart, France, developing, manufacturing, and marketing a comprehensive portfolio of implantable cardiac devices. The product portfolio includes cardiac pacemakers, implantable cardiac defibrillators (such as the ULYS ICD), cardiac resynchronization systems (CRT), and ECG diagnostic solutions for managing cardiac rhythm disorders and heart failure globally. The company focuses on connectivity in cardiac care and develops devices with advanced features targeting the global implantable cardiac devices market.

Product and service1 record
1Cardiac Pacemakers
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Largest global CRM player offering pacemakers, ICDs, CRT, and remote monitoring (CareLink). Directly competes with MicroPort CRM across the same product categories and hospital customer base.

TypeDirect peer
Description

Major CRM competitor offering ICDs, CRT-Ds, and the LATITUDE remote monitoring system. Competes head-to-head with MicroPort CRM in implantable defibrillators and resynchronization systems globally.

TypeDirect peer
Description

Inherited a leading CRM franchise through its acquisition of St. Jude Medical. Offers pacemakers, ICDs, CRT, and the Merlin remote monitoring platform, competing directly with MicroPort CRM in all major CRM categories.

TypeDirect peer
Description

Privately held German CRM specialist offering pacemakers, ICDs, CRT, and the Home Monitoring remote platform. Closely comparable as a focused, non-public CRM challenger that competes with MicroPort CRM on connectivity and innovation.

TypeDirect peer
Description

Historically a CRM player (pacemakers and ICDs) competing in the same category as MicroPort CRM, though the company has signaled potential divestiture of its CRM business. Comparable in product scope and hospital customer base.

TypeOthers
Description

Contract manufacturer supplying components and assemblies for CRM devices (pacing leads, ICDs, batteries). Comparable as a CRM-adjacent enabler serving the same downstream OEM customers that MicroPort CRM also serves or competes with.

TypeBroad incumbent
Description

Broader cardiac device incumbent with overlapping cardiology customer relationships at hospitals, though focused on structural heart and critical care rather than CRM. Comparable as a large cardiology player competing for hospital wallet share and clinician mindshare.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MicroPort CRM

Cardiac Rhythm Management Medical Devicescrm.microport.com

MicroPort CRM is a Clamart, France-based subsidiary of MicroPort Scientific Corporation that develops, manufactures, and markets implantable pacemakers, defibrillators, cardiac resynchronization systems, and ECG diagnostic solutions for hospitals and cardiac centers managing rhythm disorders and heart failure globally.

What MicroPort CRM does

MicroPort CRM develops, manufactures, and markets a portfolio of implantable cardiac devices for the management of cardiac rhythm disorders and heart failure. The company is headquartered in Clamart, near Paris, France, and operates as the Cardiac Rhythm Management-focused subsidiary of MicroPort Scientific Corporation, a publicly listed Chinese medical device conglomerate. Its product range spans cardiac pacemakers, implantable cardiac defibrillators (including the recently launched ULYS ICD), cardiac resynchronization therapy (CRT) systems for heart failure, and ECG diagnostic solutions, all positioned under a "connectivity-focused" brand thesis. The ULYS ICD and INVICTA defibrillation leads were introduced in Japan in October 2023 following clinical trials that reported a 100% implantation success rate and a 97.4% complication-free rate.

MicroPort CRM firmographics

Firmographics
Name
MicroPort CRM
Legal name
MicroPort Scientific Corporation
Website
https://crm.microport.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
5,001–10,000 employees
Short description
MicroPort CRM is a Clamart, France-based subsidiary of MicroPort Scientific Corporation that develops, manufactures, and markets implantable pacemakers, defibrillators, cardiac resynchronization systems, and ECG diagnostic solutions for hospitals and cardiac centers managing rhythm disorders and heart failure globally.
Ownership category
akta.pro rank

MicroPort CRM industry classification

Industry
Product category
Cardiac Rhythm Management Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Cardiac Rhythm Management (Pacemakers, ICDs, CRT) (HLAHAFAC)

Keywords

  • Cardiac rhythm management
  • Implantable cardiac devices
  • Cardiac pacemakers
  • Implantable defibrillators
  • Cardiac resynchronization therapy

Where MicroPort CRM is headquartered

Location

Headquarters

HQ city
Clamart
HQ country
France
HQ region
Europe

Offices1 record

Markets served

MicroPort CRM business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Implantable Cardiac Devices: Sale of implantable cardiac rhythm management devices including pacemakers, defibrillators, and cardiac resynchronization systems. Revenue is generated through product sales to hospitals and healthcare facilities globally.
  2. ECG Diagnostic Solutions: Sale of ECG diagnostic equipment and solutions for cardiac rhythm monitoring and diagnosis

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

MicroPort CRM product offering

Product offering

Core offering

MicroPort CRM develops, manufactures, and markets implantable cardiac devices for the management of cardiac rhythm disorders and heart failure. Its portfolio includes cardiac pacemakers, implantable cardiac defibrillators (including the ULYS ICD), defibrillation leads (INVICTA), cardiac resynchronization therapy (CRT) systems, and ECG diagnostic solutions, sold globally to hospitals and cardiac care centers.

Product overview

MicroPort® CRM is a pioneering Cardiac Rhythm Management (CRM) company headquartered in Clamart, France, developing, manufacturing, and marketing a comprehensive portfolio of implantable cardiac devices. The product portfolio includes cardiac pacemakers, implantable cardiac defibrillators (such as the ULYS ICD), cardiac resynchronization systems (CRT), and ECG diagnostic solutions for managing cardiac rhythm disorders and heart failure globally. The company focuses on connectivity in cardiac care and develops devices with advanced features targeting the global implantable cardiac devices market.

Differentiator

Problem solved

Functional benefit

Brands

  • CardioFlow MedTech: Cardiac rhythm management product brand mentioned on the MicroPort website linking to en.cardioflowmedtech.com

Products and services

  • Cardiac Pacemakers

Quantifiable outcome

  • 100% implantation success rate for ULYS ICD in Japan clinical trials
  • +1 more outcomes

Companies that use MicroPort CRM

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles1 record

MicroPort CRM technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

MicroPort CRM partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

MicroPort CRM competitors and assessment

Company assessment

Direct peers

  • Medtronic: Largest global CRM player offering pacemakers, ICDs, CRT, and remote monitoring (CareLink). Directly competes with MicroPort CRM across the same product categories and hospital customer base.
  • Boston Scientific: Major CRM competitor offering ICDs, CRT-Ds, and the LATITUDE remote monitoring system. Competes head-to-head with MicroPort CRM in implantable defibrillators and resynchronization systems globally.
  • Abbott: Inherited a leading CRM franchise through its acquisition of St. Jude Medical. Offers pacemakers, ICDs, CRT, and the Merlin remote monitoring platform, competing directly with MicroPort CRM in all major CRM categories.
  • BIOTRONIK: Privately held German CRM specialist offering pacemakers, ICDs, CRT, and the Home Monitoring remote platform. Closely comparable as a focused, non-public CRM challenger that competes with MicroPort CRM on connectivity and innovation.
  • LivaNova: Historically a CRM player (pacemakers and ICDs) competing in the same category as MicroPort CRM, though the company has signaled potential divestiture of its CRM business. Comparable in product scope and hospital customer base.

Others

  • Integer Holdings: Contract manufacturer supplying components and assemblies for CRM devices (pacing leads, ICDs, batteries). Comparable as a CRM-adjacent enabler serving the same downstream OEM customers that MicroPort CRM also serves or competes with.

Broad incumbents

  • Edwards Lifesciences: Broader cardiac device incumbent with overlapping cardiology customer relationships at hospitals, though focused on structural heart and critical care rather than CRM. Comparable as a large cardiology player competing for hospital wallet share and clinician mindshare.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

MicroPort CRM social profiles

Digital presence

MicroPort CRM financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MicroPort CRM leadership team

Management profile

Number of profiles

Profiles6 records

MicroPort CRM funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MicroPort CRM M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MicroPort CRM

What does MicroPort CRM do?

MicroPort CRM develops, manufactures, and markets implantable cardiac devices for the management of cardiac rhythm disorders and heart failure. Its portfolio includes cardiac pacemakers, implantable cardiac defibrillators (including the ULYS ICD), defibrillation leads (INVICTA), cardiac resynchronization therapy (CRT) systems, and ECG diagnostic solutions, sold globally to hospitals and cardiac care centers.

Is MicroPort CRM a public or private company?

MicroPort CRM is a private company. It is classified as corporate owned and is currently operating.

When was MicroPort CRM founded?

MicroPort CRM was founded in 2017. It employs 5,001 to 10,000 people.

Where is MicroPort CRM based?

MicroPort CRM is headquartered in Clamart, France, in the Europe region.

How does MicroPort CRM make money?

Two revenue lines are on record. Implantable Cardiac Devices are the primary driver. The others are ECG Diagnostic Solutions.

Who are MicroPort CRM's main competitors?

Direct peers on record are Medtronic, Boston Scientific, Abbott, BIOTRONIK and LivaNova. Integer Holdings is listed as an others. Edwards Lifesciences is listed as a broad incumbent.

Does MicroPort CRM have an API?

No public API is recorded for MicroPort CRM.

What industry is MicroPort CRM in?

MicroPort CRM's product category is Cardiac Rhythm Management Medical Devices. Its primary akta.pro industry code is HLAHAFAC, Cardiac Rhythm Management (Pacemakers, ICDs, CRT). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comCompetitive Landscape: Leading Companies and New Entrants in the Implantable Cardiac Devices MarketThe implantable cardiac devices market is projected to reach $20.33 billion by 2030, growing at a compound annual growth rate of 8.8%, driven by rising demand for remote patient monitoring, minimally invasive procedures, and digital healthcare integration. In November 2023, Johnson & Johnson MedTech acquired Laminar Inc. for $400 million to strengthen its structural-heart and left-atrial-appendage management portfolio, adding Laminar's investigational LAAX technology. In October 2023, MicroPort CRM (France) launched its ULYS implantable cardioverter defibrillator and INVICTA defibrillation leads in Japan, reporting a 100% implantation success rate and 97.4% complication-free rate in clinical trials.PR NewswireMicroPort CRM Receives Approval in Japan for Alizea Bluetooth PacemakerMicroPort CRM received PMDA regulatory approval in Japan for its Alizea Bluetooth pacemaker, which enables remote patient monitoring when paired with the SmartView Connect home monitor. The device addresses a growing need for remote cardiac care in Japan, where approximately 64,000 patients receive pacemaker implants annually. The company, a subsidiary of MicroPort Scientific Corporation, previously launched Alizea in Europe in June 2021 and plans to continue expanding the technology globally.PR NewswireMicroPort® Cardiac Rhythm Management anuncia una inversión de 150 millones de dólares estadounidensesMicroPort Scientific Corporation announced through its subsidiary MicroPort Cardiac Rhythm Management a Series C funding round totaling $150 million USD, co-led by Hillhouse Capital Group and MicroPort, with six new institutional investors including CICC, Country Garden Venture Capital, and others providing $83 million in additional capital. The funding, expected to close in early August 2021, will support expansion of the company's cardiac rhythm management product portfolio including new defibrillator systems, a subcutaneous ICD, and a leadless pacemaker. MicroPort CRM, acquired in 2018 and headquartered in Clamart, France, operates R&D centers in France and China with manufacturing facilities across four countries and serves over two million patients globally.PR NewswireMicroPort® Herzrhythmus-Management-Unternehmen gibt 150 Millionen US-Dollar-Investition der Serie C bekanntMicroPort Scientific Corporation announced that its subsidiary MicroPort Cardiac Rhythm Management Limited has signed definitive agreements for a $150 million Series C funding round, with closing expected in early August 2021 pending standard conditions. Hillhouse Capital Group and MicroPort will co-lead the round, investing $20 million and $47 million respectively, while six additional investors including CICC, Country Garden Venture Capital, and Wanhui Capital will contribute the remaining $83 million, leaving MicroPort as the majority shareholder. MicroPort CRM, acquired in April 2018 and headquartered near Paris, France, develops and manufactures pacemakers, implantable defibrillators, and cardiac resynchronization therapy devices across facilities in France, Italy, the Dominican Republic, and China.PR NewswireL'entreprise de gestion du rythme cardiaque MicroPort® annonce un investissement de série C de 150 millions de dollars USMicroPort Scientific Corporation announced that its subsidiary MicroPort Cardiac Rhythm Management Limited (MicroPort® CRM) has closed a $150 million Series C funding round, co-led by Hillhouse Capital Group and MicroPort, with six additional investors—CICC, Country Garden Venture Capital, YongRong Asset Management Ltd, L Squared Private Management, E Fund Management Co. Ltd., and Wanhui Capital—investing the remaining $83 million. MicroPort will remain the majority shareholder of MicroPort CRM upon closing, which is expected in early August 2021 pending standard conditions. The capital will support the development and market launch of MicroPort CRM's expanding product pipeline, including next-generation defibrillator systems, a subcutaneous ICD, a leadless pacemaker, and the Axone cardiac resynchronization therapy project.MicroportCRM Announces US$150M Series C InvestmentMicroPort Cardiac Rhythm Management Limited, a subsidiary of MicroPort Scientific Corporation, announced definitive agreements for a US$150 million Series C financing on 26 July 2021, co-led by Hillhouse Capital Group and MicroPort. Six new investors contributed US$83 million, with closing expected in early August 2021. The company employs about 1,100 people and has implanted over two million patients worldwide.PR NewswireImplicity Inc. Signs U.S. Distribution Agreement with MicroPort CRM USAImplicity Inc. signed a U.S. distribution agreement with MicroPort CRM USA, allowing the medical device company to sell and distribute Implicity's cloud-based remote patient monitoring software in the United States. This partnership enables cardiologists to integrate data from MicroPort's cardiac implantable electronic devices into Implicity's platform for more efficient workflow management. The deal expands Implicity's reach to U.S. healthcare providers seeking to scale cardiac remote monitoring practices.PR NewswireCardioFocus® Announces Expanded Distribution Partnership With MicroPort™ CRM To Include Spain And PortugalCardioFocus, Inc. has expanded its existing French distribution partnership with MicroPort CRM to include Spain and Portugal for its HeartLight X3 atrial fibrillation ablation system. The expansion builds on the success achieved in France, where MicroPort CRM launched the HeartLight X3 technology. The HeartLight X3 received European CE Mark approval in 2019 and uses laser technology for pulmonary vein isolation procedures.PR NewswireMicroPort CRM initiiert eine klinische Studie für die bahnbrechende innovative linksventrikuläre Elektrode Axone(TM)MicroPort Cardio Rhythm Management (CRM) has initiated the Astral-4LV clinical study to evaluate the safety and efficacy of Axone™, a quadripolar left ventricular lead for cardiac resynchronization therapy (CRT) in heart failure patients, with the first implantation performed on December 3, 2020 at Rouen University Hospital, France. The study will enroll 152 patients at 20 centers across seven European countries, with data intended to support CE marking approval of the Axone™ lead, which features a diameter of 0.4 mm and four widely spaced electrodes enabling multi-point stimulation. The Axone™ project received funding from the EU Horizon 2020 research and innovation programme, with MicroPort CRM leading collaboration alongside Heraeus GmbH, Rouen University Hospital, and Maastricht University.PR NewswireMicroPort CRM inicia un ensayo clínico para el avance del innovador cable ventricular izquierdo Axone(TM)MicroPort CRM announced the first patient enrollment in the Astral-4LV clinical trial on December 3, 2020, at Rouen University Hospital in France, to evaluate the safety and performance of its Axone™ left ventricular quadripolar lead for cardiac resynchronization therapy (CRT). The Axone™ lead features a 0.4-millimeter diameter—approximately four times smaller than standard leads—and four widely spaced electrodes designed to navigate narrow coronary veins and enable multipoint pacing. The prospective, single-arm, multicenter study will enroll 152 patients across 20 centers in seven European countries, with data supporting the device's CE marking and patients followed for four years.